Open AccessContinuation of adjuvant chemotherapy for osteosarcoma resistant to neoadjuvant treatment. Meaningful action or habit?
Author(s) -
Н. В. Жуков
Publication year - 2019
Publication title -
rossijskij žurnal detskoj gematologii i onkologii
Language(s) - English
Resource type - Journals
eISSN - 2413-5496
pISSN - 2311-1267
DOI - 10.21682/2311-1267-2019-6-1-48-55
Subject(s) - medicine , chemotherapy , methotrexate , osteosarcoma , cisplatin , doxorubicin , adjuvant chemotherapy , adjuvant , radiology , surgery , oncology , cancer , pathology , breast cancer
Chemotherapy (CT) has significantly increased the chance of cure for patients with resectable osteogenic sarcoma and is now an integral part of their treatment. At the same time, the standard approach is represented by administration of the same СT (doxorubicin, cisplatin, methotrexate) to all patients both before and after the surgery has remained unchanged over the past decades. Unfortunately, the results of its application in patients with a poor pathologic response of a tumor to preoperative CT are not satisfactory, and recently published studies have not shown their improvement due to the intensification of postoperative CT. As a result, the standard of treatment for these patients remains a continuation after surgery the same CT, which has proved ineffective at the preoperative stage. The article is devoted to a critical analysis of the feasibility of such practices and an assessment of the possible positive and negative consequences of the rejection of postoperative CT in patients with poor pathologic response.